Details of the Drug
General Information of Drug (ID: DMIN60B)
| Drug Name |
N-(pyridin-3-ylmethyl)aniline
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
N-(pyridin-3-ylmethyl)aniline; Phenyl-pyridin-3-ylmethyl-amine; 73570-11-3; phenylpyridin-3-ylmethylamine; CHEMBL264669; N-((pyridine-3-yl)methyl)benzeneamine; BAS 06103406; 3ftv; 3ftw; 11X; 3-anilinomethylpyridine; AC1LLDK0; n-(3-pyridylmethyl)aniline; phenyl(3-pyridylmethyl)amine; 3-(phenylaminomethyl)pyridine; MLS000527027; SCHEMBL523753; BJXLHKJBRORJJJ-UHFFFAOYSA-N; N-[(pyridin-3-yl)methyl]aniline; MolPort-002-003-387; ZINC798246; HMS3604C11; HMS2177I23; N-(pyridin-3-ylmethyl)benzenamine; HMS1684G18
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 184.24 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.3 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


